Objective
The treatment of cancer with chemotherapeutic drugs is very often associated with severe side effects limiting their tolerated dose and leading to insufficient therapeutic effects. The application of such drugs in nanometer-sized micelles may improve their biodistribution, but in vivo studies showed fast drug release in the blood stream. We aim for prolonged drug retention and intracellular release by introducing the stable, yet reversible Lx linker in the core of bioresorbable polymeric micelles. This coordinative platinum linker will have two functions: (1) it will facilitate the stable conjugation between the drug molecule and the polymer molecules constituting the micelle and (2) it will act as a stabilizer between the polymer molecules constituting the micelle. This will result in excellent stability of the drug-loaded micelles in circulation. Due to the enhanced permeability and retention effect the micelles will accumulate in tumor tissue, where they will be destabilized intracellularly and the drugs will be released from the linker in the cytoplasm after competitive glutathione displacement.
The Lx linker presents various advantages over other crosslink methods, such as versatility and ease of crosslinking. No platinum-related toxicity was observed in vivo for the linker in previous research. In addition, the amount of platinum may be considered negligible since powerful drugs will be loaded onto the micelles.
This approach represents a safe and unique hybrid method which has the potential to significantly increase the amount of drug deposited at the target tissue and to reduce side effects at non-target sites. By pursuing this significant step forward in cancer therapy, the fellowship will broaden the Experienced Researcher’s scientific and non-scientific skills via advanced training as well as transnational and transdisciplinary mobility. Furthermore, it will facilitate a lively transfer of knowledge between the participants due to their complementarity.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences chemical sciences inorganic chemistry transition metals
- natural sciences chemical sciences polymer sciences
- medical and health sciences medical biotechnology nanomedicine
- medical and health sciences clinical medicine oncology
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF-EF-ST - Standard EF
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2014
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
75794 PARIS
France
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.